Trasylol Could Face Labeling Changes After Joint Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Long-term observational study showing CV-renal risk for Bayer’s Trasylol should be judged in light of potentially inappropriate comparator drugs, FDA says.
You may also be interested in...
Bayer Revises Study Protocol Review To Prevent Another Trasylol Fiasco
Protocol Review Committee purview extended beyond prospective clinical trials based upon independent review findings.
Avandia’s Fate May Hang On How Advisory Cmte. Weighs Meta-Analyses Vs. Other Data
FDA notes “considerable concern” about cardiovascular signal, while GSK points to positive epidemiologic data in the run-up to the July 30 committee meeting on the diabetes drug.
JAMA Article Links Increased Long-Term Mortality To Trasylol Use In CABG Patients
Study published in Feb. 7 issue reporting negative mortality results adds to recent safety concerns regarding aprotinin use and renal dysfunction.